At least six Indian pharmaceutical companies have joined the global race to develop a novel coronavirus vaccine, giving a sector better known for making generic copies of drugs a platform to show its innovative capability.
The World Health Organization has listed three Indian companies — Zydus Cadila, Serum Institute of India and Bharat Biotech — that are working on a vaccine. In addition, Hyderabad-based companies Biological E and Indian Immunologicals as well as Bangalore-based Mynvax are also involved in development. READ MORE (CACHED ARTICLE)
Similar Posts:
- Surviving the Pharma Drug Price Wars in Emerging Markets (PharmExec.com)
- India to Offer More Investment Options Through ADRs (The Asset)
- Asia is Home to 50% of World’s Fastest Growing Companies (Nikkei Asian Review)
- Fund Manager Interview: Aberdeen India Fund (Aberdeen)
- CLSA Equity Strategist Says India is the Best BRICs Investment Destination (LM)
- How India (Mostly) Benefits From Low Oil Prices (The Economic Times)
- Is India’s lost generation a systemic risk? (CNBC)
- India Moves Up the Ranks of Asia300 Companies (Nikkei Asian Review)
- Investor Sentiment Survey: What Emerging Market Investors Think (Franklin Templeton)
- OMGI’s Crabb: India Consumer Stocks on “Very Stretched Multiples” (FE Trustnet)
- Podcast: Electric Vehicles in Emerging Markets (BNP Paribas AM)
- Why China’s Stock Market Tumble is Giving India’s a Lift (Nikkei Asia)
- moneycontrol India Stock of the Day (August 2023)
- Jubilant FoodWorks (NSE: JUBLFOOD / BOM: 533155): Inflation Bites as They Aggressively Expand Domino’s Pizza
- Indian Media Reactions as Infosys Names SAP’s Vishal Sikka as CEO
